Skip to main content
. 2025 Sep 14;272(9):632. doi: 10.1007/s00415-025-13344-1

Table 1.

Clinical and genetic data of the 24 probands

P Gene/variant ACMG AD/AR Symptoms at onset (age) Primary neurological symptom presumably related to BGC Intracerebral calcifications (TCS, 0–80) Number of bilateral locations with severe and confluent calcification (calcification score 5) WMH intensity (0–3) VRF
1 Heterozygous SLC20A2 c.1240 G > T p.(Glu144*)[19] LP, novel AD Cerebellar ataxia (SCA4, not related to BGCs) (25y) Facial twitches 10 1 No hypodensities in the white matter (CT) 0
2 Heterozygous SLC20A2 c.1220C > A p.(Ser407*) LP, novel AD Seizure (48y) Personality changes, memory problems 46 3 2 (MRI) 0
3 Heterozygous SLC20A2 c.1696A > T p.(Ile566Phe) VUSa, novel AD TIA (40y) Cognitive impairment 60 6 3 (MRI) 0
4 Heterozygous SLC20A2 c.1703C > T p.(Pro568Leu) and heterozygous PDGFRB c.1808-6C > T P/LP and VUS AD Anxiety (30y) Hearing loss, anxiety, mild personality change 40 3 No hypodensities in the white matter (CT) 0
5 Heterozygous SLC20A2 c.1703C > T p.(Pro568Leu) P/LP AD Mild cognitive impairment (60y) Stroke (67y) 8 0 3 (MRI) 1
6 Heterozygous PDGFB c.571C > T p.(Arg191*)[9] LP AD Depression, Anxiety (14y) Absence, seizure, TIAs (25y) 4 0 2 (MRI) 0
7 Heterozygous PDGFB c.418C > T p.(Gln140*)[9] LP AD Balance difficulties (64y) Balance difficulties 46 4 3 (MRI) 0
8 Homozygous MYORG c.1727G > A p.(Arg576His) LP AR Gait/balance disturbance (41y) Walking and speech difficulties 73 7 3 (MRI) 0
9 Heterozygous MAP3K6 c.322G > A p.(Asp108Asn)[20] LP AD Mild cognitive impairment (57y) Mild cognitive impairment 4 0 2 (MRI) 1
10 Heterozygous GLA c.394G > C p.(Gly132Arg) P AD Gastric pain episodes (38y) Stroke (47y) 14 0 2 (MRI) 0
11 MT-TL1 m.3243A > C P Mit Headaches/migraine (38y) Headaches 6 0 0 (MRI) 2
12 MT-TL1 m.3243A > C P Mit Derealization, headaches (21y) Headaches, depression episodes 12 0 1 (MRI) 1
13 MT-TL1 m.3243A > C P Mit Renal insufficiency and uncontrolled hypertension (23y) Cognitive impairment 20 1 2 (MRI) 4
14 MT-TL1 m.3243A > C P Mit Ophthalmoplegia (35y) Myopathy and fatigue 8 0 1 (MRI) 0
15 Negative Nd Sporadic TIA (57y) Tremor 4 0 1 (MRI) 3
16 Negative Nd Sporadic Motor polyneuropathy (40y) Motor polyneuropathy 2 0 Hypodensities in the white matter compatible with Fazekas 3 (CT) 1
17 Negative Nd AD Parkinsonism (65y) Parkinsonism 4 0 Hypodensities in the white matter compatible with Fazekas 1 (CT) 2
18 Negative Nd Sporadic Headaches (24y) Headaches/Parkinsonism 4 0 No hypodensities in the white matter (CT) 0
19 Negative Nd Sporadic Essential tremor (45y) Stroke (54y) 48 4 2 (MRI) 0
20 Negative Nd Sporadic Seizures (19y) Walking difficulties 34 2 2 (MRI) 0
21 Negative Nd Sporadic Seizures (28y) Seizures 4 0 1 (MRI) 0
22 Negative Nd Sporadic Balance disturbance (35y) Balance difficulties, speech difficulties 58 4 2 (MRI) 0
23 Negative Nd Sporadic Balance disturbance, speech difficulties (32y) Balance difficulties, speech difficulties 2 0 1 (MRI) 0
24 Negative Nd Sporadic Psychotic episodes (42y) Seizures 4 0 1 (MRI) 0

ACMG American college of medical genetics, AD autosomal dominant, AR autosomal recessive, BGC basal ganglia calcifications, Nd not determined, LP likely pathogenic, Mit mitochondrial, P pathogenic, TCS total calcification score, TIA transitory ischemic attack, VUS variant of unknown significance, WMH white matter hyperintensities, VRF vascular risk factors: hypertension; diabetes; hyperlipidemia; heart disease or smoking, y years of age

asame variant also identified in son who had BGC and neurological symptoms, see Case Vignette in Results section